Not long after lending its support to a documentary aimed at shining on light on the often-overlooked stories of women with hemophilia, Sanofi is continuing its film-focused collaboration with patient ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the Advisory Committee on Immunization Practices (ACIP)—whose appointment was ...

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

China has approved the world's first commercial brain-computer interface. AstraZeneca is building new cell therapy centers in Shanghai. | China approved the world's first commercial brain-computer ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to ...

In a bid to expand its reach in the attention-deficit/hyperactivity disorder (ADHD) market, Collegium Pharmaceutical has struck a deal to ...

Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...

Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of ...

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly ...